For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative volunteer for the Breast Disease Site Committee.
Please join CCTG on April 10 from 11:00 to 12:00 pm EST for a virtual round table on strategies for improving equity and access in cancer clinical trials. We are honoured to bring together Dr. Don S. Dizon and Dr. Sara Moore to guide us in this conversation which will be moderated by Dr. Janet Dancey. The goal of this discussion is to help participants consider strategies for enhancing clinical trial diversity and making clinical trials more accessible to all populations that may benefit from them.
Now open the CCTG PR24 ASCENDE-SBRT trial to determine whether stereotactic body radiotherapy (SBRT) can replace the current standard radiation treatment (brachytherapy boost) for men with unfavourable risk prostate cancer. SBRT is a non-invasive, high precision, less costly radiation technique that results in similar outcomes and tolerability to brachytherapy boost.
The results of the CX5/SHAPE clinical trial, published today in the New England Journal of Medicine (NEJM), conclude that a simple hysterectomy is a safe treatment option for women with low-risk early-stage cervical cancer. The Phase III international trial compared radical hysterectomy and pelvic node dissection with simple hysterectomy and pelvic node dissection.
